MARKET

BMEA

BMEA

Biomea Fusion, Inc.
NASDAQ
1.710
-0.120
-6.56%
After Hours: 1.730 +0.02 +1.17% 19:30 09/21 EDT
OPEN
1.840
PREV CLOSE
1.830
HIGH
1.850
LOW
1.675
VOLUME
1.79M
TURNOVER
--
52 WEEK HIGH
2.990
52 WEEK LOW
0.8719
MARKET CAP
123.95M
P/E (TTM)
-3.4448
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BMEA last week (0914-0918)?
Weekly Report · 1d ago
Weekly Report: what happened at BMEA last week (0907-0911)?
Weekly Report · 09/14 09:09
Weekly Report: what happened at BMEA last week (0831-0904)?
Weekly Report · 09/07 09:08
Weekly Report: what happened at BMEA last week (0824-0828)?
Weekly Report · 08/31 09:09
Biomea Fusion Completes Key Phase 2 Trial in Type 1 Diabetes: What Investors Should Watch Next
TipRanks · 08/28 16:30
Biomea Fusion Stock Surges on Phase II Diabetes Trial Enrollment Completion
Benzinga · 08/24 20:05
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 08/24 17:06
Biomea Fusion Reaffirmed at Buy as Icoviamenib Phase 2 Strategy Advances; $4 Price Target Maintained
TipRanks · 08/24 13:55
More
About BMEA
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies, including icovamenib and BMF-650, for diabetes and obesity, with research activities focused on the biology of metabolic diseases. Its covalent small molecule drug is a synthetic compound that forms a permanent bond with its target protein. The Company’s clinical candidate, icovamenib, is an investigational oral small molecule that reversibly downmodulates menin, a transcriptional regulator involved in beta-cell biology. Its Phase 2 clinical development includes type 1 and type 2 diabetes, obesity, and combination with GLP-1 receptor agonist therapies. The Company’s second product candidate, BMF-650, is an investigational, oral small-molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA), for the treatment of diabetes and obesity.

Webull offers Biomea Fusion Inc stock information, including NASDAQ: BMEA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMEA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMEA stock methods without spending real money on the virtual paper trading platform.